医学
药理学
胰高血糖素样肽-1
传统医学
受体
内科学
内分泌学
糖尿病
2型糖尿病
作者
Bin Zhu,Nian Gong,Hui Fan,Chongsheng Peng,Xiujuan Ding,Yi Jiang,Yong‐Xiang Wang
出处
期刊:Anesthesiology
[Lippincott Williams & Wilkins]
日期:2014-09-24
卷期号:121 (4): 835-851
被引量:57
标识
DOI:10.1097/aln.0000000000000320
摘要
Abstract Background: Lamiophlomis rotata is an orally available Tibetan herb prescribed for the management of pain, with shanzhiside methylester (SM) and 8- O -acetyl-SM as quality control ingredients. This study aimed to evaluate the antinociceptive properties of L. rotata , determine whether SM and 8- O -acetyl-SM are principle effective ingredients, and explore whether L. rotata produces antinociception through activation of spinal glucagon-like peptide-1 receptors (GLP-1Rs). Methods: Formalin test, neuropathic pain, and bone cancer pain models were used, and the animal sample size was 5 to 6 in each group. Hydrogen peroxide–induced oxidative damage was also assayed. Results: The L. rotata aqueous extract blocked formalin-induced tonic hyperalgesia and peripheral nerve injury– and bone cancer–induced mechanical allodynia by 50 to 80%, with half-effective doses of 130 to 250 mg/kg, close to the human dosage. The herb was not effective in alleviating acute nociceptive pain. A 7-day gavage with L. rotata aqueous extract did not lead to antiallodynic tolerance. Total iridoid glycosides, rather than total flavonoids, were identified by the activity-tracking method as effective ingredients for antihyperalgesia, whereas both SM and 8- O -acetyl-SM were principal components. Further demonstrations using the GLP-1R antagonist and gene silencer against GLP-1R at both the spinal and the cellular levels indicated that L. rotata inhibited pain hyperactivity by activation of spinal GLP-1Rs, and SM and 8- O -acetyl-SM appeared to be orthosteric, reversible, and fully intrinsic agonists of both rat and human GLP-1Rs. Conclusions: Results support the notion that the activation of spinal GLP-1Rs leads to specific antinociception in pain hypersensitivity and further suggest that GLP-1R is a human-validated target molecule for the treatment of chronic pain.
科研通智能强力驱动
Strongly Powered by AbleSci AI